Emotional and Clinical Challenges of Delayed HIV Seroconversion – Case Study
DOI:
https://doi.org/10.57125/FEM.2024.09.30.03Keywords:
HIV, HIV-1, HIV infection, HIV testing, seroconversion, HIV seropositivity, AIDS serodiagnosisAbstract
Aims: to examine the emotional and clinical impact of delayed HIV seroconversion in a 36-year-old male healthcare professional in Ecuador.
Methodology: a case report analysis that included patient history, clinical presentation, and treatment outcomes.
Results: severe anxiety, depression, and perceived risk of death due to delayed ART initiation. Symptoms of weight loss and profuse sweating resolved after ART and psychiatric treatment.
Scientific Novelty: the paper highlights the complexities of delayed HIV diagnosis and its profound emotional impact, emphasising the need for regular testing and comprehensive mental health support.
Conclusion: timely HIV testing and integrated medical and emotional care are critical for managing delayed seroconversion.
References
World Health Organization. HIV and AIDS [Internet]. Geneva: World Health Organization; 2023 [cited 2023 Oct 1]. Available from: https://www.who.int/news-room/fact-sheets/detail/hiv-aids.
Waymack JR, Sundareshan V. Acquired Immune Deficiency Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
GeSIDA, editor. Documento de consenso de GeSIDA/ División de Control de VIH, ITS, Hepatitis virales y Tuberculosis del Ministerio de Sanidad respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. 2023rd ed. España: Ministerio de Sanidad; 2023.
European AIDS Clinical Society, editor. EACS Guidelines 2022. Version 11.1. European AIDS Clinical Society (EACS); 2022.
Wells N, Murphy D, Ellard J, Philpot SP, Prestage G, on behalf of the RISE Study Team. HIV Diagnosis as Both Biographical Disruption and Biographical Reinforcement: Experiences of HIV Diagnoses Among Recently Diagnosed People Living With HIV. Qual Health Res. 2023;33:165–75. doi: 10.1177/10497323221146467.
Wells N, Prestage G, Murphy D, et al. Patient-centred approaches to providing care at HIV diagnosis: perspectives from healthcare and peer-support workers. Sex Health. 2022;19:448–55. doi: 10.1071/SH22052.
Murphy D, Wells N, Ellard J, Prestage G. Experiences of HIV seroconversion, diagnosis, and linkage to care: Report on findings from a qualitative study of people recently diagnosed with HIV. Sydney: UNSW Sydney; 2023. doi: 10.26190/JMY5-GY97.
Henn A, Flateau C, Gallien S. Primary HIV Infection: Clinical Presentation, Testing, and Treatment. Curr Infect Dis Rep. 2017;19:37. doi: 10.1007/s11908-017-0588-3.
Matsumoto S, Murata Y, Tomoda Y. Acute HIV infection in a 39-year-old man. CMAJ [Internet]. 2022;194(45):E1541–E1541. Available from: http://dx.doi.org/10.1503/cmaj.220656
Triebelhorn J, Haschka S, Hesse F, et al. Acute HIV infection syndrome mimicking COVID-19 vaccination side effects: a case report. AIDS Res Ther. 2021;18:78. doi: 10.1186/s12981-021-00407-2.
Ladzinski AT, George NB, Jagger BW. Bilateral peripheral facial paralysis during pregnancy: a presentation of acute HIV seroconversion. BMJ Case Rep [Internet]. 2021;14(5):e242150. Available from: http://dx.doi.org/10.1136/bcr-2021-242150
Jariwal R, Jaber FS, Ipalawatte H, Petersen G. An Unusual Case of Hemophagocytic Lymphohistiocytosis Presentation in Acute Human Immunodeficiency Virus. J Investig Med High Impact Case Rep. 2021;9:23247096211021696. doi: 10.1177/23247096211021696.
Delaney KP, Hanson DL, Masciotra S, Ethridge SF, Wesolowski L, Owen SM. Time Until Emergence of HIV Test Reactivity Following Infection With HIV-1: Implications for Interpreting Test Results and Retesting After Exposure. Clin Infect Dis. 2017;64:53–9. doi: 10.1093/cid/ciw666.
US Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for HIV Infection: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;321:2326. doi: 10.1001/jama.2019.6587.
Ministerio de Salud Pública. Prevention, diagnosis and treatment of human immunodeficiency virus (HIV) infection in pregnant women, children, adolescents and adults. 2019th ed. Quito (Ecuador): Dirección Nacional de Normatización – MSP; 2019.
Alrubayyi A, Rowland-Jones S, Peppa D. Natural killer cells during acute HIV-1 infection: clues for HIV-1 prevention and therapy. AIDS. 2022;36:1903–15. doi: 10.1097/QAD.0000000000003319.
Ekabe CJ, Clinton NA, Kehbila J, Franck NC. The Role of Inflammasome Activation in Early HIV Infection. J Immunol Res. 2021;2021:1-7. doi: 10.1155/2021/1487287.
Elliott T, Sanders EJ, Doherty M, et al. Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review. J Int AIDS Soc. 2019;22. doi: 10.1002/jia2.25419.
Flexner C, Owen A, Siccardi M, Swindells S. Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agents. 2021;57:106220. doi: 10.1016/j.ijantimicag.2020.106220.
Kazer SW, Walker BD, Shalek AK. Evolution and Diversity of Immune Responses during Acute HIV Infection. Immunity. 2020;53:908-24. doi: 10.1016/j.immuni.2020.10.015.
Zhao AV, Crutchley RD, Guduru RC, Ton K, Lam T, Min AC. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. Retrovirology. 2022;19:22. doi: 10.1186/s12977-022-00608-1.
Rodriguez NR, Fortune T, Vuong T, Swartz TH. The role of extracellular ATP and P2X receptors in the pathogenesis of HIV-1. Curr Opin Pharmacol. 2023;69:102358. doi: 10.1016/j.coph.2023.102358.
Acuña-Castillo C, Escobar A, García-Gómez M, Bachelet VC, Huidobro-Toro JP, Sauma D, Barrera-Avalos C. P2X7 Receptor in Dendritic Cells and Macrophages: Implications in Antigen Presentation and T Lymphocyte Activation. IJMS. 2024;25:2495. doi: 10.3390/ijms25052495.
Hendricks CM, Cordeiro T, Gomes AP, Stevenson M. The Interplay of HIV-1 and Macrophages in Viral Persistence. Front Microbiol. 2021;12:646447. doi: 10.3389/fmicb.2021.646447.
Louvain De Souza T, De Souza Campos Fernandes RC, Medina-Acosta E. HIV-1 Control in Battlegrounds: Important Host Genetic Variations for HIV-1 Mother-To-Child Transmission and Progression to Clinical Pediatric AIDS. Future Virol. 2012;7:659-78. doi: 10.2217/fvl.12.49.
Pontillo A, Brandão LA, Guimarães RL, Segat L, Athanasakis E, Crovella S. A 3′UTR SNP in NLRP3 Gene is Associated With Susceptibility to HIV-1 Infection. JAIDS J Acquir Immune Defic Syndr. 2010;54:236-40. doi: 10.1097/QAI.0b013e3181dd17d4.
Reis EC, Leal VNC, Da Silva LT, Dos Reis MML, Argañaraz ER, Oshiro TM, Pontillo A. Antagonistic role of IL-1ß and NLRP3/IL-18 genetics in chronic HIV-1 infection. Clin Immunol. 2019;209:108266. doi: 10.1016/j.clim.2019.108266.
De Freitas Dutra V, Leal VNC, Fernandes FP, Souza CRL, Figueiredo MS, Pontillo A. Genetic contribution and functional impairment of inflammasome in sickle cell disease. Cytokine. 2022;149:155717. doi: 10.1016/j.cyto.2021.155717.
Zheng X, Wan J, Tan G. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in diabetic retinopathy. Front Immunol. 2023;14:1151185. doi: 10.3389/fimmu.2023.1151185.
Zhang C, Song J-W, Huang H-H, et al. NLRP3 inflammasome induces CD4+ T cell loss in chronically HIV-1–infected patients. J Clin Invest. 2021;131. doi: 10.1172/JCI138861.
Min AK, Fortune T, Rodriguez N, Hedge E, Swartz TH. Inflammasomes as mediators of inflammation in HIV-1 infection. Transl Res. 2023;252:1-8. doi: 10.1016/j.trsl.2022.07.008.
World Health Organization. Antiretroviral medication Dolutegravir (DTG, Tivicay, Tivicay PD) [Internet]. Geneva: WHO; [cited 2024 May 22]. Available from: https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/dolutegravir.
Kengo A, Nabisere R, Gausi K, et al. Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin. Antimicrob Agents Chemother. 2023;67. doi: 10.1128/aac.00430-23.
Mercadel CJ, Skelley JW, Kyle JA, Elmore LK. Dolutegravir: An Integrase Strand Transfer Inhibitor for the Treatment of Human Immunodeficiency Virus 1 in Adults. J Pharm Technol. 2014;30:216-26. doi: 10.1177/8755122514544126.
Fantauzzi A, Mezzaroma I. Dolutegravir: clinical efficacy and role in HIV therapy. Ther Adv Chronic Dis. 2014;5:164-77. doi: 10.1177/2040622314530461.
Committee for Medicinal Products for Human Use. Tivicay. The Netherlands: European Medicines Agency; 2020.
World Health Organization. HIV drug resistance. 2024th ed. Geneva: World Health Organization; 2024.
World Health Organization. WHO recommends long-acting cabotegravir for HIV prevention [Internet]. Geneva: WHO; 2022 [cited 2024 May 22]. Available from: https://www.who.int/news/item/28-07-2022-who-recommends-long-acting-cabotegravir-for-hiv-prevention.
Agrahari V, Anderson SM, Peet MM, Wong AP, Singh ON, Doncel GF, Clark MR. Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges. Expert Opin Drug Deliv. 2022;19:1365-80. doi: 10.1080/17425247.2022.2135699.
Parikh UM, Koss CA, Mellors JW. Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance? Curr HIV/AIDS Rep. 2022;19:384-93. doi: 10.1007/s11904-022-00616-y.
Liegeon G, Ghosn J. Long‐acting injectable cabotegravir for PrEP: A game‐changer in HIV prevention? HIV Med. 2023;24:653-63. doi: 10.1111/hiv.13451.
Collins S, Namiba A, Sparrowhawk A, Strachan S, Thompson M, Nakamura H. Late diagnosis of HIV in 2022: Why so little change? HIV Med. 2022;23:1118-26. doi: 10.1111/hiv.13444.
Rava M, Bisbal O, Domínguez-Domínguez L, et al. Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment. AIDS. 2021;35:1283-93. doi: 10.1097/QAD.0000000000002891.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
